IP Library › Patent Application 14061989
Patent Application
App. No. 14/061,989

SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/061,989
Abstract

The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Claims (7)

1 . A method of treating juvenile idiopathic arthritis (JIA) in a patient comprising subcutaneously administering an anti-IL-6 receptor (IL-6R) antibody to the patient in an amount effective to treat the JIA.

2 . The method of claim 1 wherein the JIA is systemic JIA (sJIA).

3 . The method of claim 2 wherein the effective amount is 162 mg every week if the patient's weight is ≧30 kilograms.

4 . The method of claim 2 wherein the effective amount is 162 mg every 10 days if the patient's weight is <30 kilograms.

5 . The method of claim 1 wherein the JIA is polyarticular course juvenile idiopathic arthritis (pcJIA).

6 . The method of claim 5 wherein the effective amount is 162 mg every two weeks.

7 . The method of claim 1 wherein the anti-IL-6R antibody is tocilizumab.